PRESS RELEASE: Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture

Cambridge, UK and Yokohama, Japan- Qkine Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, and REPROCELL Inc., Japan's first and leading induced pluripotent stem cell (iPSC) company, have partnered to globally distribute high-quality proteins such as growth factors and cytokines manufactured by Qkine.

Qkine has specialist expertise in the design and manufacture of complex growth factors, such as the TGF beta family, using animal-origin free manufacturing processes and achieving exceptional biochemical purity and bioactivities.

"We are happy to partner with Qkine and expand our offering in high quality proteins globally. Through REPROCELL's network, Qkine's growth factors and cytokines will be introduced to stem cell scientists globally to support their research and manufacturing workflows such as stem cell maintenance, differentiations, and 3D organoid culture. Qkine also has established their manufacturing processes as animal origin-free with full traceability, which is one of the key considerations in therapeutic applications." said Chikafumi Yokoyama Ph.D., CEO of REPROCELL Inc.

"We are delighted to collaborate with REPROCELL to enable advances in stem cell research and manufacturing through combining our recombinant protein expertise and innovative bioactive protein portfolio with REPROCELL's expert stem cell knowhow and workflow solutions." said Catherine Elton Ph.D., CEO of Qkine Ltd.

About Qkine Ltd.

Qkine manufactures high-purity, animal origin-free growth factors, cytokines, and other complex proteins for life science applications, including stem cell and organoid culture. Headquartered in Cambridge, UK, the company addresses critical biological, quality, and scalability challenges through proprietary recombinant protein production processes combined with advanced protein engineering techniques. Its commitment to innovation supports emerging fields such as stem cell models, organoids, cellular agriculture, cell therapy, regenerative medicine, and organ-on-a-chip technologies. By delivering more reliable tools for research and biomanufacturing, Qkine seeks to accelerate the impact of these technologies on human health and wellbeing.

Qkine is an ISO 9001:2015 certified company, providing full traceability and extensive product documentation. Exceptional transparency, the Qkine Nine Point Quality Commitment, and integrated scientific support are designed to facilitate scale-up and commercial cell manufacturing.

For more information, please visit qkine.com, email [email protected] or follow Qkine on LinkedIn.

About REPROCELL Inc.

REPROCELL (4978: TSE) was established in 2003 with a goal of contributing to people's health and welfare through the development of stem cell technologies. REPROCELL successfully went public in 2013 as the first iPS cell company on the Tokyo Stock Exchange Market, and then started to expand their business both globally and rapidly through several M&As. REPROCELL is pursuing two business areas of Discovery and Medical using proprietary human cell technologies including stem cells, biorepository, bioengineered tissue and drug screening. REPROCELL has developed a proprietary process to manufacture integration-free, virus-free and clinically relevant human iPSC lines using proprietary RNA reprogramming technology. This process is suitable for manufacturing robust, consistent and high-quality functional cells at commercial scale for use in both pre-clinical and clinical development applications.

For more information, see www.reprocell.com.